What is Zacks Research's Estimate for STERIS Q2 Earnings?

Key Points

• STERIS plc's Q2 2026 earnings per share estimates have been revised down from $2.82 to $2.37, with the full-year earnings consensus at $9.08.
• The company recently declared a quarterly dividend of $0.63 per share, marking an increase from the previous $0.57 dividend.
• Institutional investors own approximately 94.69% of STERIS stock, indicating significant confidence in the company among major shareholders.

STERIS plc (NYSE:STE - Free Report) - Zacks Research lowered their Q2 2026 earnings per share (EPS) estimates for STERIS in a research report issued on Tuesday, September 16th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings of $2.37 per share for the quarter, down from their previous forecast of $2.82. The consensus estimate for STERIS's current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS's Q3 2026 earnings at $2.57 EPS, Q4 2026 earnings at $2.85 EPS, FY2026 earnings at $10.13 EPS, Q1 2027 earnings at $2.46 EPS, Q2 2027 earnings at $2.86 EPS, Q3 2027 earnings at $2.79 EPS, Q4 2027 earnings at $2.64 EPS, FY2027 earnings at $10.75 EPS, Q1 2028 earnings at $3.01 EPS and FY2028 earnings at $12.21 EPS.

A number of other equities research analysts have also weighed in on STE. Jefferies Financial Group started coverage on STERIS in a research note on Thursday, May 29th. They issued a "hold" rating and a $263.00 target price for the company. Morgan Stanley upped their target price on STERIS from $276.00 to $295.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 14th. Finally, KeyCorp upped their price target on STERIS from $277.00 to $288.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $273.50.

STERIS Trading Up 0.2%

Shares of NYSE STE traded up $0.53 during midday trading on Thursday, reaching $249.31. The company had a trading volume of 133,262 shares, compared to its average volume of 589,131. STERIS has a one year low of $200.98 and a one year high of $253.00. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The firm's fifty day moving average price is $239.18 and its 200-day moving average price is $234.07. The stock has a market cap of $24.55 billion, a PE ratio of 38.18 and a beta of 0.95.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.02. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The firm had revenue of $1.40 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter in the previous year, the company posted $2.03 earnings per share. The company's revenue was up 8.8% compared to the same quarter last year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 26th. Investors of record on Thursday, September 4th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. This is a positive change from STERIS's previous quarterly dividend of $0.57. The ex-dividend date of this dividend is Thursday, September 4th. STERIS's payout ratio is presently 38.59%.

Insider Buying and Selling at STERIS

In other STERIS news, Director Mohsen Sohi sold 4,110 shares of STERIS stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.96, for a total value of $994,455.60. Following the transaction, the director directly owned 22,361 shares of the company's stock, valued at approximately $5,410,467.56. The trade was a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Karen L. Burton sold 7,900 shares of the business's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.73, for a total transaction of $1,909,667.00. Following the sale, the chief accounting officer directly owned 5,994 shares in the company, valued at $1,448,929.62. This trade represents a 56.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,709 shares of company stock worth $4,546,940. 1.07% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Osaic Holdings Inc. lifted its position in STERIS by 2.8% during the second quarter. Osaic Holdings Inc. now owns 10,376 shares of the medical equipment provider's stock valued at $2,484,000 after purchasing an additional 287 shares during the period. American Trust acquired a new position in STERIS during the second quarter valued at $222,000. Orion Porfolio Solutions LLC lifted its position in STERIS by 5.5% during the second quarter. Orion Porfolio Solutions LLC now owns 15,204 shares of the medical equipment provider's stock valued at $3,652,000 after purchasing an additional 788 shares during the period. Thrivent Financial for Lutherans raised its position in shares of STERIS by 49.2% in the second quarter. Thrivent Financial for Lutherans now owns 159,864 shares of the medical equipment provider's stock worth $38,402,000 after acquiring an additional 52,746 shares during the period. Finally, Neuberger Berman Group LLC raised its position in shares of STERIS by 64.7% in the second quarter. Neuberger Berman Group LLC now owns 19,416 shares of the medical equipment provider's stock worth $4,664,000 after acquiring an additional 7,630 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.